GlaxoSmithKline, a science-led global healthcare company, completed the acquisition of Affinivax, a clinical-stage biopharmaceutical company, for $3.3bn. “The proposed acquisition further strengthens our vaccines R&D pipeline, provides access to a new, potentially disruptive technology, and broadens GSK’s existing scientific footprint in the Boston area. We look forward to working with the many talented people at Affinivax to combine our industry-leading development, manufacturing, and commercialisation capabilities to make this exciting new technology available to those in need," Hal Barron, GSK Chief Scientific Officer.